Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of F-652 plus systemic corticosteroids for acute graft-versus-host disease after HSCT
CTR20262536Phase 2Active
- Sponsor
- Evive Biotech
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of eflepedocokin alfa in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Evive Biotech. Started Sep 2026; status: active.
02
Drugs
eflepedocokin alfa
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20262536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262536.